Cysteine 230 modulates tumor necrosis factor-related apoptosis-inducing ligand activity

Cancer Research

Volumn 60, Issue 12, 2000, Pages 3152-3154

  Seol, Dai Wu ^a   Billiar, Timothy R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISULFIDE BOND; HELA CELL; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CYSTEINE; DIMERIZATION; DISULFIDES; DITHIOTHREITOL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLYCINE; HELA CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034123874     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ashkenazi, A., and Dixit, V. M. Death receptors: signaling and modulation. Science (Washington DC), 281: 1305-1308, 1998.
2. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
3. Salvesen, G. S., and Dixit, V. M. Caspases: intracellular signaling by proteolysis. Cell. 91: 443-446, 1997.
4. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett. I. L., Camonis, J. H., and Wallach, D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270: 7795-7798, 1995.
5. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 81: 505-512, 1995.
6. Chinnaiyan, A. M., Tepper, C. G., Seldin, M. F., O'Rourke, K., Kischkel, F. C., Hellbardt, S., Krammer, P. H., Peter, M. E., and Dixit, V. M. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem., 271: 4961-4965, 1996.
7. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death Cell, 85: 803-815, 1996.
8. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85: 817-827, 1996.
9. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. S. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. USA, 93: 14486-14491, 1996.
10. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3: 673-682, 1995.
11. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271: 12687-12690, 1996.
12. Cha. S. S., Kim, M. S., Choi, Y. H., Sung, B. J., Shin, N. K., Shin, H. C., Sung, Y. C., and Oh, B. H. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity, 11: 253-261, 1999.
13. Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and Dixit, V. M. The receptor for the cytotoxic ligand TRAIL. Science (Washington DC), 276: 111-113, 1997.
14. Pan, G., Ni, J., Wei, Y. F., Yu, G., Gentz, R., and Dixit, V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (Washington DC), 277, 815-818, 1997.
15. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., and Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (Washington DC), 277: 818-821, 1997.
16. MacFarlane, M., Ahmad, M., Srinivasula, S. M., Fernandes-Alnemri, T., Cohen, G. M., and Alnemri, E. S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem., 272: 25417-25420, 1997.
17. Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., and Ashkenazi, A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol., 7: 1003-1006, 1997.
18. Seol, D. W., and Billiar, T. R. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J. Biol. Chem., 274: 2072-2076, 1999.
19. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C., Schuh, J. C., and Lynch, D. H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 5: 157-163, 1999.
20. Jeremias, I., Herr, I., Boehler, T., and Debatin, K. M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol., 28: 143-152, 1998.
21. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature (Lond.), 364: 806-809, 1993.
22. Galle, P. R., Hofmann, W. J., Waltzak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. H., and Runkel, L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med., 182: 1223-1230, 1995.
23. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 104: 155-162, 1999.
24. Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F., Ashkenazi, A., and de Vos, A. M. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell. 4: 563-571, 1999.
25. Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A. M., and Kelley, R. F. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry, 39: 633-640, 2000.